Sponsors (2)
The bill strengthens screening, oversight, and transparency for DNA sequence orders to reduce biological risk and improve supply-chain accountability, but it brings compliance costs, potential delays for legitimate research, and privacy and federalism concerns.
The general public, researchers, and health officials: improved screening and mandatory notification processes reduce the risk that dangerous genetic sequences are acquired or misused, enhancing public safety.
Researchers and biotech companies: clearer standards and guidance for screening DNA orders reduce legal uncertainty around legitimate sales and make it easier for compliant actors to operate.
Covered entities and trading partners: independent assessments and recordkeeping requirements increase accountability and can bolster trust in the biotech supply chain and export/commercial credibility.
Small biotech suppliers, labs, and startups: compliance will impose administrative and technical costs that could raise prices, create burdens, and squeeze smaller firms.
Scientists, hospitals, and product developers: buyer verification and purpose vetting may slow access to sequences and delay research, clinical work, or product development.
Researchers and the scientific community: identifying and listing 'covered sequences' and controlling submissions risks exposing sensitive sequence information or hampering scientific openness if not carefully handled.
Based on analysis of 2 sections of legislative text.
Requires sellers of nucleic acid sequences to verify buyers, screen uses, apply risk‑based refusals, notify the Secretary of high‑risk misuse, conduct independent assessments, and keep records for five years.
Official title: To improve the security of nucleic acid synthesis in interstate and foreign commerce, and for other purposes.
Introduced August 31, 2026 by August Pfluger · Last progress August 31, 2026
Requires companies and other entities that sell or otherwise make nucleic acid sequences available across state or international lines to set up programs that verify buyers, assess buyer purpose, screen sequences for risk, refuse high‑risk sales with documentation, and report credible threats to a federal official. It also requires independent compliance checks, record retention, and directs the Secretary to issue guidance, enforcement priorities, and a notification/coordination mechanism on a set timetable. The law focuses on controlling access to sequences deemed risky for misuse, standardizing verification and refusal practices, creating reporting and coordination channels with the federal government, and establishing regular third‑party or adversarial testing to assure compliance.